PARP1 Inhibitor HRS-1167 clinical trials
Also written HRS-1167.
Its developmentBy Merck KGaA, Darmstadt, Germany and Jiangsu HengRui Medicine, step by step6 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses PARP1 Inhibitor HRS-1167 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the PARP1 Inhibitor HRS-1167 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
EMD Serono Research & Development Institute, Inc. (3) · Jiangsu HengRui Medicine Co., Ltd. (2) · Fudan University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of PARP inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test PARP1 Inhibitor HRS-1167.
- Dec 2026Study of HRS-1167 as Monotherapy in Patients With Advanced Solid TumorsPhase 1 · Jiangsu HengRui Medicine Co., Ltd.
- Feb 2027M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Phase 1 · EMD Serono Research & Development Institute, Inc.
Studies
Open first, then newest update. How each study uses PARP1 Inhibitor HRS-1167 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and PrednisoneRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06689163Written as HRS-1167 tablets
- Study of HRS-1167 as Monotherapy in Patients With Advanced Solid TumorsRecruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05473624Written as HRS-1167
- Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± CamrelizumabRecruitingPhase 2Fudan UniversityNCT06516289Written as HRS-1167
- M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruitingPhase 1EMD Serono Research & Development Institute, Inc.NCT06421935Written as M9466
- M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)TerminatedPhase 1EMD Serono Research & Development Institute, Inc.NCT06509906Written as M9466
- Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)WithdrawnPhase 1EMD Serono Research & Development Institute, Inc.NCT06719973Written as M9466